Charles Schwab Investment Management Inc Beam Therapeutics Inc. Transaction History
Charles Schwab Investment Management Inc
- $519 Billion
- Q2 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 593,266 shares of BEAM stock, worth $14.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
593,266
Previous 579,272
2.42%
Holding current value
$14.9 Million
Previous $19.1 Million
27.37%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding BEAM
# of Institutions
230Shares Held
73.6MCall Options Held
283KPut Options Held
233K-
Farallon Capital Management LLC San Francisco, CA7.91MShares$198 Million0.9% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.9MShares$198 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$191 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.63MShares$191 Million1.63% of portfolio
-
Arch Venture Management, LLC Chicago, IL5.44MShares$136 Million74.72% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.76B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...